Piperacillin +tazobactam

# Piperacillin +tazobactam ## Overview - **Classification**: Penicillin antibiotic (extended-spectrum) + Beta-lactamase inhibitor - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases. ## Primary Indications 1. **Nosocomial Pneumonia** - Including ventilator-associated pneumonia (VAP). 2. **Intra-abdominal Infections** - Complicated appendicitis, peritonitis, abscesses. 3. **Skin and Skin Structure Infections** - Complicated infections, diabetic foot infections. 4. **Bacteremia** - Empiric therapy for severe sepsis or septic shock. ## Adult Dosing ### Standard Dosing **Most Infections (e.g., CAP, cIAI, cSSTIs)** - **Dose**: **3.375 g IV** - **Frequency**: Every 6 hours - **Route**: Intravenous (IV) - **Special consideration**: Often given as a 30-minute infusion. Extended infusion (over 3-4 hours) may be preferred for critically ill patients. **Nosocomial Pneumonia (e.g., HAP/VAP)** - **Dose**: **4.5 g IV** - **Frequency**: Every 6 hours - **Route**: Intravenous (IV) - **Special consideration**: Extended infusion (over 3-4 hours) is often recommended. ### Dose Adjustments - **Renal Impairment**: Based on estimated CrCl. - **CrCl > 40 mL/min**: No adjustment needed. - **CrCl 20-40 mL/min**: **3.375 g IV** every 8 hours. - **CrCl < 20 mL/min**: **2.25 g IV** every 6-8 hours. - **Hemodialysis**: **2.25 g IV** every 8 hours, with an additional **0.75 g** dose given after each dialysis session. - **Hepatic Impairment**: No specific dosage adjustment guidelines. Monitor for adverse effects. - **Elderly Patients**: Adjust dose based on renal function, as age can lead to decreased CrCl. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Sepsis, hospital-acquired infections (off-label for some uses). - **Dose**: (Piperacillin component) - **Weight < 2 kg**: **50 mg/kg/dose IV** - **Age 0-7 days**: Every 12 hours - **Age 8-28 days**: Every 8 hours - **Weight ≥ 2 kg**: **75 mg/kg/dose IV** - **Age 0-7 days**: Every 8 hours - **Age 8-28 days**: Every 6 hours - **Maximum**: Not to exceed adult total daily dose. Limit based on mg/kg dosing. - **Special Notes**: Longer infusion durations (e.g., 30 mins to 1 hour) may be considered. Closely monitor for renal and CNS effects. ### Infants (1-12 months) - **Indication**: Complicated appendicitis, other serious infections. - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6-8 hours - **Maximum**: **3.375 g/dose** (piperacillin 3g/tazobactam 0.375g) - **Special Notes**: Administer over 30 minutes. ### Children (1-12 years) - **Indication**: Complicated intra-abdominal infections, cSSTIs, nosocomial pneumonia. - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6 hours - **Maximum**: **4.5 g/dose** (piperacillin 4g/tazobactam 0.5g) or **18 g/day** (piperacillin component) - **Special Notes**: Consider extended infusion for severe infections. ### Adolescents (13-18 years) - **Dose**: Follow **adult dosing** recommendations. - **Maximum**: **4.5 g/dose** (pip/tazo) or **18 g/day** (piperacillin component). ## Safety Information ### Contraindications - **Absolute**: History of severe hypersensitivity (e.g., anaphylaxis, SJS) to piperacillin/tazobactam, penicillins, cephalosporins, or other beta-lactam antibiotics. - **Absolute**: Known history of cholestatic jaundice/hepatic dysfunction associated with piperacillin/tazobactam. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, Nausea. - **Common (1-10%)**: Headache, Constipation, Rash, Vomiting, Insomnia, Fever, Anemia. - **Serious but Rare**: Anaphylaxis, Clostridium difficile-associated diarrhea (CDAD), Seizures (especially with renal impairment), Neutropenia/Thrombocytopenia, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN). ### Key Drug Interactions - **Methotrexate**: Concurrent use can increase methotrexate levels, leading to toxicity. Avoid co-administration or closely monitor methotrexate levels. - **Vecuronium**: Prolongs neuromuscular blockade of vecuronium and other non-depolarizing muscle relaxants. Monitor for respiratory depression. - **Warfarin**: Can alter INR, requiring close monitoring and possible dose adjustment of warfarin. - **Valproic Acid**: Piperacillin/tazobactam may decrease valproic acid serum levels, potentially leading to loss of seizure control. Monitor valproic acid levels. ## Monitoring & Follow-up - **Before Treatment**: Obtain culture and sensitivity tests. Check baseline renal function (CrCl), liver function tests (LFTs), and complete blood count (CBC). - **During Treatment**: - **Renal function**: Monitor CrCl, BUN, creatinine daily in critically ill; every 2-3 days otherwise. - **Hepatic function**: Monitor LFTs weekly. - **Hematologic**: Monitor CBC with differential weekly, especially for prolonged therapy (>2 weeks). - **Clinical Signs**: Monitor for signs of hypersensitivity reaction, C. diff infection, and new neurological symptoms (e.g., seizures). - **Clinical Signs**: Watch for rash, urticaria, wheezing (hypersensitivity). Report persistent diarrhea. Monitor for signs of bleeding or infection (e.g., fever, sore throat) due to hematologic effects. ## Clinical Pearls - 💡 **Tip 1**: Extended infusion (over 3-4 hours) is often preferred for critically ill patients to optimize time above MIC (T>MIC), improving efficacy. - 💡 **Tip 2**: Consider the significant sodium load (**2.79 mEq/g** of piperacillin) in patients with heart failure or hypertension. - 💡 **Tip 3**: Educate patients on potential for diarrhea and to seek medical attention if severe or bloody. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.